Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dr Reddys Laboratories (RDY) Receivables (2017 - 2025)

Dr Reddys Laboratories (RDY) has 8 years of Receivables data on record, last reported at $967.0 million in Q1 2024.

  • For Q1 2024, Receivables rose 9.65% year-over-year to $967.0 million; the TTM value through Mar 2024 reached $967.0 million, up 9.65%, while the annual FY2024 figure was $970.1 million, 7.36% up from the prior year.
  • Receivables reached $967.0 million in Q1 2024 per RDY's latest filing, up from $881.9 million in the prior quarter.
  • Across five years, Receivables topped out at $967.0 million in Q1 2024 and bottomed at $683.0 million in Q1 2021.
  • Average Receivables over 5 years is $827.8 million, with a median of $881.9 million recorded in 2023.
  • Peak YoY movement for Receivables: dropped 4.88% in 2021, then surged 30.19% in 2022.
  • A 5-year view of Receivables shows it stood at $718.0 million in 2020, then decreased by 4.88% to $683.0 million in 2021, then skyrocketed by 30.19% to $889.1 million in 2022, then fell by 0.82% to $881.9 million in 2023, then increased by 9.65% to $967.0 million in 2024.
  • Per Business Quant database, its latest 3 readings for Receivables were $967.0 million in Q1 2024, $881.9 million in Q1 2023, and $889.1 million in Q1 2022.